Evidence map›Paper›PMID 40410932›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

STING deletion protects against amyloid β-induced Alzheimer's disease pathogenesis.

Jessica M Thanos, Olivia C Campbell, Maureen N Cowan, Katherine R Bruch, Katelyn A Moore, Hannah E Ennerfelt, Nick R Natale, Aman Mangalmurti, Nagaraj Kerur, John R Lukens

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Microglial CLEC7A restrains amyloid beta plaque pathology in a mouse model of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  16. STING deletion protects against amyloid β-induced Alzheimer's disease pathogenesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica M ThanosDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0001-7984-5361
Olivia C CampbellDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.
Maureen N CowanDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.
Katherine R BruchDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Katelyn A MooreDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.
Hannah E EnnerfeltDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Nick R NataleDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.
Aman MangalmurtiDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.
Nagaraj KerurDepartment of Ophthalmology and Visual Sciences, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
John R LukensDepartment of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0002-6795-0866

Funding

The Ohio State University Vision Sciences Research Core Program (OSU-VSRCP)P30EY032857 · NEI · OHIO STATE UNIVERSITY · PI ANDY J FISCHER · 2022 to 2026
$3.6M
Making a case for CASS4 in Alzheimer's diseaseR01AG087406 · NIA · UNIVERSITY OF VIRGINIA · PI John R Lukens · 2024 to 2026
$1.7M
CLEC7A in microglia biology and Alzheimer's diseaseRF1AG078684 · NIA · UNIVERSITY OF VIRGINIA · PI LUKENS, JOHN R · 2023 to 2023
$1.6M
Brain, Immunology and Glia Training ProgramT32NS115657 · NINDS · UNIVERSITY OF VIRGINIA · PI Alban P Gaultier, TAJIE H. HARRIS · 2021 to 2026
$1.2M
Role of the SYK-CARD9 signaling axis in Alzheimer's diseaseR01AG071996 · NIA · UNIVERSITY OF VIRGINIA · PI LUKENS, JOHN R · 2024 to 2025
$1.1M
Exploring the role of hyper-phagocytic microglia and SYK signaling in the aged hippocampus during COVID-19F31NS135897 · NINDS · UNIVERSITY OF VIRGINIA · PI Nick Natale · 2023 to 2026
$107k
Alzheimer's Association ADSF-21-816651Cure Alzheimer's Fund GrantHarrison Family FoundationNEI NIH HHS P30 EY032857NIA NIH HHS R01 AG071996NIA NIH HHS R01 AG087406NIA NIH HHS RF1 AG078684NIA NIH HHS RF1AG078684NIH HHS R01AG071996NIH HHS R01AG087406NIH HHS RF1AG078684NINDS NIH HHS F31 NS135897NINDS NIH HHS T32 NS115657NINDS NIH HHS T32NS115657Owens Family Foundation Grant
6 · The paper itself

Abstract

introductionWhile immune dysfunction has been increasingly linked to Alzheimer's disease (AD) progression, many major innate immune signaling molecules have yet to be explored in AD pathogenesis using genetic targeting approaches.

methodsTo investigate a role for the key innate immune adaptor molecule, stimulator of interferon genes (STING), in AD, we deleted Sting1 in the 5xFAD mouse model of AD-related amyloidosis and evaluated the effects on pathology, neuroinflammation, gene expression, and cognition.

resultsGenetic ablation of STING in 5xFAD mice led to improved control of amyloid beta (Aβ) plaques, alterations in microglial activation status, decreased levels of neuritic dystrophy, and protection against cognitive decline. Moreover, rescue of neurological disease in STING-deficient 5xFAD mice was characterized by reduced expression of type I interferon signaling genes in both microglia and excitatory neurons. DISCUSSION: These findings reveal critical roles for STING in Aβ-driven neurological disease and suggest that STING-targeting therapeutics may offer promising strategies to treat AD. HIGHLIGHTS: Stimulator of interferon genes (STING) deficiency in the 5xFAD mouse model of Alzheimer's disease-related amyloidosis results in decreased amyloid beta (Aβ) deposition and altered microglial activation status. Protection against amyloidosis in STING-deficient 5xFAD mice is associated with decreased expression of genes involved in type I IFN signaling, improved neuronal health, and reduced levels of oxidative stress. Loss of STING in 5xFAD mice leads to improved spatial learning and memory.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesMembrane ProteinsAnimalsDisease Models, AnimalHumansMiceMice, TransgenicMicrogliaPlaque, AmyloidSTING ProteinAmyloid beta-PeptidesMembrane ProteinsSting1 protein, mouseSTING ProteinAlzheimer's diseaseamyloid betaamyloidosisinnate immunitymicroglianeurodegenerative diseaseneuroimmunologySTING

Identifiers

PMID40410932
PMCPMC12101966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.